COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking

Al-Salama, 2019, Emapalumab: first global approval, Drugs, 79, 99, 10.1007/s40265-018-1046-8 Arabi, 2018, Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial, Trials, 19, 81, 10.1186/s13063-017-2427-0 Bacharier, 2015, Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial, JAMA, 314, 2034, 10.1001/jama.2015.13896 Begum-Haque, 2008, Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis, J. Neuroimmunol., 204, 58, 10.1016/j.jneuroim.2008.07.018 Bekerman, 2017, Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects, J. Clin. Invest., 127, 1338, 10.1172/JCI89857 Bester, 2016, Effects of IL-1beta, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity, Sci. Rep., 6, 32188, 10.1038/srep32188 Bester, 2018, Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1beta, IL-6 and IL-8, Cytokine, 110, 237, 10.1016/j.cyto.2018.01.007 Bjorn, 2015, The impact of ruxolitinib treatment on inflammation-mediated comorbidities in myelofibrosis and related neoplasms, Clin. Case Rep., 3, 499, 10.1002/ccr3.281 Brown, 2019, Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase, Antiviral Res., 169, 10.1016/j.antiviral.2019.104541 Caly, 2020, The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res., 10.1016/j.antiviral.2020.104787 Cao, 2020, A trial of Lopinavir-Ritonavir in adults hospitalized with severe Covid-19, N. Engl. J. Med., 382, 1787, 10.1056/NEJMoa2001282 Chan, 2003, Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study, Hong Kong Med. J., 9, 399 Chan, 2013, Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus, J. Infect., 67, 606, 10.1016/j.jinf.2013.09.029 Chan, 2015, Treatment with Lopinavir/Ritonavir or Interferon-beta1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset, J. Infect. Dis., 212, 1904, 10.1093/infdis/jiv392 Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, 395, 507, 10.1016/S0140-6736(20)30211-7 Chen, 2020, A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19, J Zhejiang Univ (Med Sci), 49, 215 Chen, 2020, Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, medRxiv Cheng, 2020, 2019 Novel coronavirus: where we are and what we know, Infection, 10.1007/s15010-020-01401-y Choi, 2006, The relationship between inflammation and the coagulation system, Swiss Med., 136, 139 Choi, 2018, Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease, Leukemia, 32, 2483, 10.1038/s41375-018-0123-z Chu, 2004, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax, 59, 252, 10.1136/thorax.2003.012658 Coomes, 2020, Interleukin-6 in COVID-19: a systematic review and meta-analysis, medRxiv 2020 https://clinicaltrials.gov/. COVID-19 Clinical Trials. Cui, 2020, Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia, J. Thromb. Haemost., 10.1111/jth.14830 Daughtry, 2013, Structural basis for the divergence of substrate specificity and biological function within HAD phosphatases in lipopolysaccharide and sialic acid biosynthesis, Biochemistry, 52, 5372, 10.1021/bi400659k Day, 2009, A new mouse-adapted strain of SARS-CoV as a lethal model for evaluating antiviral agents in vitro and in vivo, Virology, 395, 210, 10.1016/j.virol.2009.09.023 de Jonge, 2003, Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects, Clin. Diagn. Lab. Immunol., 10, 495, 10.1128/CDLI.10.3.495-497.2003 de Wilde, 2014, Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture, Antimicrob. Agents Chemother., 58, 4875, 10.1128/AAC.03011-14 de Wit, 2020, Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection, Proc. Natl. Acad. Sci. U. S. A., 10.1073/pnas.1922083117 Delmar, 2015, Structural basis for the regulation of the MmpL transporters of Mycobacterium tuberculosis, J. Biol. Chem., 290, 28559, 10.1074/jbc.M115.683797 Devaux, 2020, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int. J. Antimicrob. Agents, 10.1016/j.ijantimicag.2020.105938 Dong, 2014, Structural basis for outer membrane lipopolysaccharide insertion, Nature, 511, 52, 10.1038/nature13464 Dong, 2020, Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China, bioRxiv Dong, 2020, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discov. Ther., 14, 58, 10.5582/ddt.2020.01012 Edrington, 2011, Structural basis for the interaction of lipopolysaccharide with outer membrane protein H (OprH) from Pseudomonas aeruginosa, J. Biol. Chem., 286, 39211, 10.1074/jbc.M111.280933 Elli, 2019, Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib, Front. Oncol., 9, 1186, 10.3389/fonc.2019.01186 Eren, 2012, Structural basis for activation of an integral membrane protease by lipopolysaccharide, J. Biol. Chem., 287, 23971, 10.1074/jbc.M112.376418 Esmon, 1999, Inflammation, sepsis, and coagulation, Haematologica, 84, 254 Fang, 2015, Structural basis for full-spectrum inhibition of translational functions on a tRNA synthetase, Nat. Commun., 6, 6402, 10.1038/ncomms7402 Febvre-James, 2018, Repression of interferon beta-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages, Int. Immunopharmacol., 54, 354, 10.1016/j.intimp.2017.11.032 Fogarty, 2020, COVID-19 coagulopathy in caucasian patients, Br. J. Haematol. Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, 10.1016/j.ijantimicag.2020.105949 Gautret, 2020, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Travel Med. Infect. Dis., 10.1016/j.tmaid.2020.101663 Giamarellos-Bourboulis, 2020, Complex immune dysregulation in COVID-19 patients with severe respiratory failure, Cell Host Microbe, 10.1016/j.chom.2020.04.009 Glas, 2013, Bronchoalveolar hemostasis in lung injury and acute respiratory distress syndrome, J. Thromb. Haemost., 11, 17, 10.1111/jth.12047 Gong, 2020, Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia, medRxiv Gordon, 2020, The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus, J. Biol. Chem. Gordon, 2020, Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency, J. Biol. Chem., 295, 6785, 10.1074/jbc.RA120.013679 Gralinski, 2018, Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis, mBio, 9, 10.1128/mBio.01753-18 Han, 2006, Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor, Virology, 350, 15, 10.1016/j.virol.2006.01.029 Hart, 2014, Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays, J. Gen. Virol., 95, 571, 10.1099/vir.0.061911-0 Hsueh, 2004, Patient data, early SARS epidemic, Taiwan, Emerg. Infect. Dis., 10, 489, 10.3201/eid1003.030571 Hui, 2020, The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China, Int. J. Infect. Dis., 91, 264, 10.1016/j.ijid.2020.01.009 Hung, 2020, Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, Lancet, 10.1016/S0140-6736(20)31042-4 Jiang, 2018, Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV, Emerg. Microbes Infect., 7, 77, 10.1038/s41426-018-0063-8 Johnson, 1996, The proinflammatory cytokine response to coagulation and endotoxin in whole blood, Blood, 87, 5051, 10.1182/blood.V87.12.5051.bloodjournal87125051 Johnson, 1998, Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation, J. Immunol., 160, 5130, 10.4049/jimmunol.160.10.5130 Kahn, 1999, Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin, J. Clin. Invest., 103, 879, 10.1172/JCI6042 Kawase, 2012, Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry, J. Virol., 86, 6537, 10.1128/JVI.00094-12 Kerr, 2001, Interleukin 6 and haemostasis, Br. J. Haematol., 115, 3, 10.1046/j.1365-2141.2001.03061.x Khan, 2017, A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome, Crit. Care, 21, 234, 10.1186/s13054-017-1823-x Kivitz, 2016, FRI0209 MORAb-022, an anti-granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody (MAB): results of the first study in patients with mild-to-Moderate rheumatoid arthritis (RA), Ann. Rheum. Dis., 75, 507, 10.1136/annrheumdis-2016-eular.3186 Kollias, 2020, Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action, Br. J. Haematol., 10.1111/bjh.16727 Kubo, 2019, Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update, Expert Rev. Clin. Immunol., 15, 693, 10.1080/1744666X.2019.1608821 Lamb, 2018, Sarilumab: a review in moderate to severe rheumatoid arthritis, Drugs, 78, 929, 10.1007/s40265-018-0929-z Lauer, 2020, The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application, Ann. Intern. Med., 10.7326/M20-0504 Levi, 2005, Two-way interactions between inflammation and coagulation, Trends Cardiovasc. Med., 15, 254, 10.1016/j.tcm.2005.07.004 Levi, 2010, Inflammation and coagulation, Crit. Care Med., 38, S26, 10.1097/CCM.0b013e3181c98d21 Li, 2008, Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis?, Anticancer Agents Med. Chem., 8, 64, 10.2174/187152008783330824 Li, 2020, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat. Rev. Drug Discov., 19, 149, 10.1038/d41573-020-00016-0 Li, 2003, Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus, Nature, 426, 450, 10.1038/nature02145 Li, 2020, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, N. Engl. J. Med., 382, 1199, 10.1056/NEJMoa2001316 Li, 2020, Coronavirus infections and immune responses, J. Med. Virol., 92, 424, 10.1002/jmv.25685 Libby, 2002, Inflammation and atherosclerosis, Circulation, 105, 1135, 10.1161/hc0902.104353 Linlin Zhang, 2020, Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors, Science Liu, 2020, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov., 6, 16, 10.1038/s41421-020-0156-0 Madrid, 2015, Evaluation of ebola virus inhibitors for drug repurposing, ACS Infect. Dis., 1, 317, 10.1021/acsinfecdis.5b00030 Magro, 2020, SARS-CoV-2 and COVID-19: what are our options? Where should we focus our attention on to find new drugs and strategies?, Travel Med. Infect. Dis., 10.1016/j.tmaid.2020.101685 Magro, 2020, SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the’ culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc, Cytokine: X Malato, 2015, The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes, Blood Transfus., 13, 559 Maschalidi, 2016, Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice, Blood, 128, 60, 10.1182/blood-2016-02-700013 Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 Mesa, 2010, Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis, IDrugs, 13, 394 Mulangu, 2019, A randomized, controlled trial of ebola virus disease therapeutics, N. Engl. J. Med., 381, 2293, 10.1056/NEJMoa1910993 Nagata, 2008, Mouse-passaged severe acute respiratory syndrome-associated coronavirus leads to lethal pulmonary edema and diffuse alveolar damage in adult but not young mice, Am. J. Pathol., 172, 1625, 10.2353/ajpath.2008.071060 Nutho, 2020, Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms, Biochemistry, 59, 1769, 10.1021/acs.biochem.0c00160 Okabayashi, 2006, Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections, J. Med. Virol., 78, 417, 10.1002/jmv.20556 Ozdogan, 2017, Canakinumab for the treatment of familial Mediterranean fever, Expert Rev. Clin. Immunol., 13, 393, 10.1080/1744666X.2017.1313116 Ozolina, 2016, Activation of coagulation and fibrinolysis in acute respiratory distress syndrome: a prospective pilot study, Front. Med. (Lausanne), 3, 64 Poterucha, 2017, More than an anticoagulant: Do heparins have direct anti-inflammatory effects?, Thromb. Haemost., 117, 437, 10.1160/TH16-08-0620 Qin, 2020, Dysregulation of immune response in patients with COVID-19 in Wuhan, China, Clin. Infect. Dis. Quintas-Cardama, 2010, Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms, Blood, 115, 3109, 10.1182/blood-2009-04-214957 Quiros Roldan, 2020, The possible mechanisms of action of 4-aminoquinolines (chloroquine/hydroxychloroquine) against Sars-Cov-2 infection (COVID-19): A role for iron homeostasis?, Pharmacol. Res., 158, 10.1016/j.phrs.2020.104904 Ramirez, 2018, Anakinra for the treatment of rheumatoid arthritis: a safety evaluation, Expert Opin. Drug Saf., 17, 727, 10.1080/14740338.2018.1486819 https://www.recoverytrial.net/results RECOVERY Trial, 2020. Regnault, 2003, Platelet activation induced by human antibodies to interleukin-8, Blood, 101, 1419, 10.1182/blood-2002-02-0620 Reitsma, 2004, Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study, J. Thromb. Haemost., 2, 619, 10.1111/j.1538-7836.2004.00689.x Retallack, 2016, Zika virus cell tropism in the developing human brain and inhibition by azithromycin, Proc. Natl. Acad. Sci. U. S. A., 113, 14408, 10.1073/pnas.1618029113 Rose-John, 2017, The soluble interleukin 6 receptor: advanced therapeutic options in inflammation, Clin. Pharmacol. Ther., 102, 591, 10.1002/cpt.782 Rothman, 2018, Canakinumab for atherosclerotic disease, N. Engl. J. Med., 378, 197 Russell, 2020, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet (London, England), 395, 473, 10.1016/S0140-6736(20)30317-2 Sanders, 2020, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, JAMA, 10.1001/jama.2020.6019 Senchenkova, 2013, Interleukin-6 mediates the platelet abnormalities and thrombogenesis associated with experimental colitis, Am. J. Pathol., 183, 173, 10.1016/j.ajpath.2013.03.014 Senolt, 2019, Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies, F1000Res, 8, 10.12688/f1000research.18688.1 Shang, 2020, Structural basis of receptor recognition by SARS-CoV-2, Nature, 10.1038/s41586-020-2179-y She, 2020, 2019 novel coronavirus of pneumonia in Wuhan, China: emerging attack and management strategies, Clin. Transl. Med., 9, 19, 10.1186/s40169-020-00271-z Sheahan, 2017, Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses, Sci. Transl. Med., 9, 10.1126/scitranslmed.aal3653 Sheahan, 2020, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat. Commun., 11, 222, 10.1038/s41467-019-13940-6 Shukla, 2001, Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry, J. Clin. Invest., 108, 503, 10.1172/JCI200113799 Spiezia, 2020, COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure, Thromb. Haemost., 10.1055/s-0040-1714350 Stebbing, 2020, COVID-19: combining antiviral and anti-inflammatory treatments, Lancet Infect. Dis., 10.1016/S1473-3099(20)30132-8 Tang, 2020, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J. Thromb. Haemost., 18, 844, 10.1111/jth.14768 Tang, 2020, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J. Thromb. Haemost. Thachil, 2020, ISTH interim guidance on recognition and management of coagulopathy in COVID-19, J. Thromb. Haemost., 18, 1023, 10.1111/jth.14810 van Aken, 2002, Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis, Br. J. Haematol., 116, 173, 10.1046/j.1365-2141.2002.03245.x Vannucchi, 2017, Emerging treatments for classical myeloproliferative neoplasms, Blood, 129, 693, 10.1182/blood-2016-10-695965 Verstovsek, 2010, Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis, N. Engl. J. Med., 363, 1117, 10.1056/NEJMoa1002028 Vicenzi, 2004, Coronaviridae and SARS-associated coronavirus strain HSR1, Emerg. Infect. Dis., 10, 413, 10.3201/eid1003.030683 Walls, 2020, Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein, Cell, 10.1016/j.cell.2020.02.058 Wang, 2004, Temporal relationship of viral load, ribavirin, interleukin (IL)-6, IL-8, and clinical progression in patients with severe acute respiratory syndrome, Clin. Infect. Dis., 39, 1071, 10.1086/423808 Wang, 2020, Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China, Clin. Infect. Dis. Wang, 2020, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 10.1016/S0140-6736(20)31022-9 Wang, 2020, Fingolimod inhibits proliferation and epithelial-mesenchymal transition in sacral chordoma by inactivating IL-6/STAT3 signalling, Biosci. Rep., 40 Wang, 2020 Weiss, 2011, Coronavirus pathogenesis, Adv. Virus Res., 81, 85, 10.1016/B978-0-12-385885-6.00009-2 Wichmann, 2020, Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study, Ann. Intern. Med., 10.7326/M20-2003 Widjaja, 2019, Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein, Emerg. Microbes Infect., 8, 516, 10.1080/22221751.2019.1597644 Wrapp, 2020, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 1260, 10.1126/science.abb2507 Wu, 2020, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern. Med., 10.1001/jamainternmed.2020.0994 Yao, 2020, A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option, J. Med. Virol., 10.1002/jmv.25729 Young, 2008, The anti-inflammatory effects of heparin and related compounds, Thromb. Res., 122, 743, 10.1016/j.thromres.2006.10.026 Zhang, 2007, Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB, Virology, 365, 324, 10.1016/j.virol.2007.04.009 Zhang, 2020, Coagulopathy and antiphospholipid antibodies in patients with Covid-19, N. Engl. J. Med., 10.1056/NEJMc2007575 Zhou, 2015, Protease inhibitors targeting coronavirus and filovirus entry, Antiviral Res., 116, 76, 10.1016/j.antiviral.2015.01.011 Zhou, 2020, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J. Antimicrob. Chemother. Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3 Zhou, 2020, Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients, Sci. Rev.